Blockchain Registration Transaction Record

OS Therapies' Osteosarcoma Treatment Advances Toward FDA Approval

OS Therapies advances OST-HER2 immunotherapy for osteosarcoma with FDA RMAT designation. Phase 2b results show significant survival improvement. Potential 2026 launch with commercial partner Eversana.

This development represents a potential breakthrough for pediatric and young adult cancer patients, particularly those with osteosarcoma who have had no new treatment options for over four decades. The accelerated regulatory pathway and strong clinical data suggest OST-HER2 could soon become available, offering hope for improved survival outcomes. For investors, the combination of clinical success, regulatory momentum, and financial positioning makes this a significant opportunity in the biotech sector, with potential for substantial returns given the orphan drug status and Priority Review Voucher possibility.